A better screening for a better care
The growing challenges of pandemic risk management for infectious diseases drives the need for decentralized diagnostic solutions. More than 120 million high-risk populations need to be screened on an infectious disease panel in western countries alone. That is why European health authorities and WHO are both looking for assays providing full serological status on the 3 mains blood borne diseases : HIV, Hepatitis B & C .
To fulfill this need, MagIA diagnostic develops a platform that enables the detection of infection diseases panels. The in vitro diagnostic platform is dedicated to point of care multiplex panel testing using capillary blood. MagIA detects 4 to 8 parameters in only 20 minutes based on a combination of an instrument (Analyzer) and consumables (Kits).
Our key for a flexible and simple solution
MagIA diagnostics analyzer presents many benefits:
- Portability, with 2 removable batteries autonomy of up to 8 hours,
- Analyze of either 1 or 2 cartridges in parallel,
- Objective and qualitative results of 4 parameters in 20 minutes.
MagIA diagnostics analyzer can be upgraded using the following accessories:
- Mini-printer, for patient results printing,
- Handle scanner, for patient input identification.
The simple way of blood sampling
Each MagIA kits is composed of a cartridge, a lancet, a pipette and a pre-filled diluent dropper bottle.
How does it work?
- Collect 50 µl capillary blood using lancet and pipette
- Dilute blood in the dropper bottle
- Fill the cartridge
- Insert the cartridge in MagIA analyzer
- Get 4 results in 20 minutes
Innovative rapid and portable panel testing
MagIA diagnostics platform is:
Flexible: Depending on patient profile & risks, possibility of testing 4 parameters.
Simple: The tests work with capillary blood. The analyzer interface is simple and intuitive.
Safe: Objective results are delivered by analyzer. 1 internal control ensure the validity of the results.
Generic: Our platform is generic so that any immunological test or panel can be implemented.
Blood borne diseases screening panel
Syndromic screening of HIV, Hepatitis B & C
MagIA diagnostics infectious diseases panel detects HIV, Hepatitis B & C all in once. The rapid and accurate knowledge of the presence or absence of the related pathogens help make timely decisions about treatment, vaccination, and infection control. From a single capillary blood sample, MagIA IBC diseases panel detects the pathogens that most commonly present a co-infection: HIV, Hepatitis B & C.
MagIA IBC properties
Collect 50 µl of sample, dilute in the provided bottle and inject into 1 cartridge
Time to results
20 minutes after cartridge insertion into MagIA Analyzer
Capillary blood, veinous blood, serum, plasma
Expected Shelf life and Storage
12 months at room temperature
MagIA IBC is the first assay dedicated to multiparametric near patient testing of HIV, Hepatitis B & C all in once. By detecting the Hepatitis B Surface Antigen (HbsAg), along with HCV and HIV-1/2 antibodies.
Our MagIA assay will be dedicated to multiparametric near patient testing of Hepatitis C and HIV. By detecting HIV-1/2 antibodies, p24 antigen and HCV antibodies, this assay allows for early detection of HIV infection and/or present or past HCV infection.
Our MagIA assay will be dedicated to multiparametric near patient testing of Hepatitis B. It can identify the presence of the Hepatitis B Surface Antigen (HbsAg), along with the related anti-HBs and anti-HBc antibodies. Thus, this kit allows for a rapid decision for a patients vaccination or for an eventual Hepatitis B treatment.
Syphilis is a recrudescent infectious disease that requires a more thorough diagnostic screening. Thus, we will implement a Syphilis MagIA assay into a blood borne diseases screening panel.
A tropical fever kit will allow the parallel detection of Dengue fever, Chikungunya and Zika.